Last reviewed · How we verify
H077 sustained-release tablet
H077 sustained-release tablet is a medication that works by inhibiting the reuptake of a specific neurotransmitter.
H077 sustained-release tablet is a medication that works by inhibiting the reuptake of a specific neurotransmitter. Used for Major depressive disorder.
At a glance
| Generic name | H077 sustained-release tablet |
|---|---|
| Sponsor | Shanghai Huilun Pharmaceutical Co., Ltd. |
| Drug class | norepinephrine reuptake inhibitor |
| Target | norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Depression |
| Phase | Phase 3 |
Mechanism of action
This action results in increased levels of the neurotransmitter in the synaptic cleft, leading to enhanced neurotransmission. The sustained-release formulation allows for a prolonged duration of action, providing consistent therapeutic effects over an extended period.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H077 sustained-release tablet CI brief — competitive landscape report
- H077 sustained-release tablet updates RSS · CI watch RSS
- Shanghai Huilun Pharmaceutical Co., Ltd. portfolio CI